ELSEVIER

Toxicology 105 (1995) 443

TOXICOLOGY

# Author index

## Volume 105 (1995)

Abbott, B.D. **105**, 365
Adams, N. **105**, 211
Ahn, H. **105**, 199
Aujoulat, M., **105**, 81

Barton, C.N. **105**, 199
Beck, B.D. **105**, 429
Bingham, E. **105**, 429
Birnbaum, L.S. **105**, 391
Boyes, W.K. **105**, 345
Brain, J.D. **105**, 429
Brendel, K. **105**, 285
Brown, L.A.S. **105**, 267

Calabrese, E.J. **105**, 121
Carr, R.L. **105**, 291
Cassee, F.R. **105**, 415
Cavagnaro, J.A., **105**, 1
Chambers, J.E. **105**, 291
Chen, J.J. **105**, 199
Condevaux, F., **105**, 81

Davis, M.E. **105**, 343
Dayan, A., **105**, 59
DeMarini, D.M. **105**, 429
DeRosa, C.T. **105**, 109, 145
Descotes, J., **105**, 31, 81
DeVito, M.J. **105**, 391
Dyer, R.S. **105**, 109

Evans, M.V. **105**, 209

Feron, V.J. **105**, 415
Fisher, R.L. **105**, 285

Gandolfi, A.J. **105**, 285
Gennings, C. **105**, 189
Gerrity, T.R. **105**, 327
Gessner, P.K. **105**, 161
Gilmour, M.I. **105**, 335
Greco, W.R. **105**, 157
Groten, J.P. **105**, 415

Hans Carter, Jr, W. **105**, 181
Hertzberg, R.C. **105**, 137, 199, 429
Hodgson, E. **105**, 211

Johnson, B.L. **105**, 145
Jones, D.P. **105**, 267
Jonker, D. **105**, 415

Kammuller, M.E., **105**, 91
Kavlock, R.J. **105**, 235
Kenyon, E.M. **105**, 225
Kodell, R.L. **105**, 199
Koren, H.S. **105**, 305
Krishnan, K. **105**, 355

Levi, P.E. **105**, 211
Lipinskas, T. **105**, 375
Lippmann, M. **105**, 305

MacPhail, R.C. **105**, 343
Mass, M.J. **105**, 403
Mathews, H.B. **105**, 209
Medinsky, M.A. **105**, 225
Mehendale, H.M. **105**, 251
Michaud, J.-P. **105**, 285
Mumtaz, M.M. **105**, 387

Nesnow, S. **105**, 403

O'Flaherty, E.J. **105**, 429

Pelekis, M. **105**, 355
Plaa, G.L. **105**, 235
Pounds, J.G. **105**, 429
Pryor, G.T. **105**, 345

Raucy, J.L. **105**, 217
Rebert, C.S. **105**, 345
Ross, J.A. **105**, 403
Ryffel, B., **105**, 69
Ryu, D.-Y. **105**, 211

Samet, J.M. **105**, 307
Sauer, J.-M. **105**, 237
Schlesinger, R.B. **105**, 315
Schlosser, P.M. **105**, 225
Schoeny, R. **105**, 283
Schwartz, R.W. **105**, 345
Sexton, K. **105**, 429
Sgro, C., **105**, 23
Silkworth, J.B. **105**, 375
Simmons, J.E. **105**, 111
Sipes, I.G. **105**, 237
Springer, J.A. **105**, 199
Sternberg, P. **105**, 267
Stoner, C.R. **105**, 375
Stoner, G.D. **105**, 403
Svendsgaard, D.J. **105**, 157, 345

Teuschler, L.K. **105**, 137
Thomas, J.A., **105**, 7

van Bladeren, P.J. **105**, 415
Verdier, F., **105**, 81,
Vial, T., **105**, 31

Waters, M.D. **105**, 387

Yang, R.S.H. **105**, 275

Zenick, H. **105**, 283

0020-7101/95/$09.50 © 1995 Elsevier Science Ireland Ltd. All rights reserved

ELSEVIER

Toxicology 105 (1995) 445–450

TOXICOLOGY

# Subject index

## Volume 105 (1995)

**Acetylcholinesterase**; Organophosphate; Insecticide; Acute toxicity; Species differences **105**, 291

**Acute phase reaction**; Interleukin-6; Recombinant human interleukin-6; Megakaryopoiesis; Immune response91-107

**Acute toxicity**; Organophosphate; Acetylcholinesterase; Insecticide; Species differences **105**, 291

**Additivity**; Bootstrap; Conservatism; Likelihood ratio; Monte Carlo; Multistage model **105**, 199

**Additivity**; Synergism; Antagonism; Carcinogen; Promotion; Interaction **105**, 121

**Ah receptor**; TCDD; Glucocorticoid; Dioxin; Paiate **105**, 365

**Air pollutant**; Asthma; Antigen; Allergy; Immunity **105**, 335

**Air pollution**; Chemical mixtures; Epidemiology **105**, 307

**Air pollution**; Risk assessment; Chemical mixtures **105**, 315

**Allergy**; Asthma; Antigen; Air pollutant; Immunity **105**, 335

**Antagonism**; Additivity; Synergism; Carcinogen; Promotion; Interaction **105**, 121

**Antagonism**; Interaction index; Contour of constant response; Response surface; Departures from additivity; Synergism; Isobologram **105**, 181

**Antigen**; Asthma; Allergy; Air pollutant; Immunity **105**, 335

**Antioxidants**; Glutathione; Peroxides, detoxication of; Detoxication, role of glutathione in; Apoptosis, redox regulation of; Blood plasma, GSH content in; Demographic factors affecting GSH; Diet, GSH content in **105**, 267

**Apoptosis, redox regulation of**; Antioxidants; Peroxides, detoxication of; Detoxication, role of glutathione in; Glutathione; Blood plasma, GSH content in; Demographic factors affecting GSH; Diet, GSH content in **105**, 267

**Asthma**; Allergy; Antigen; Air pollutant; Immunity **105**, 335

**Autoimmunity**; Cytokines; Interferons; Interleukin-2; G-CSF; GM-CSF; Side-effects; Immune disorders **105**, 31

**Benzene**; Phenol; Hydroquinone; Competitive inhibition **105**, 225

**Benzodioxoles**; Synergists; Cytochrome P450; Inhibition; Induction; Methylenedioxyphenyl compounds; Biphasic response **105**, 211

**Bioactivation**; Risk assessment; Chemical mixtures; Cytochrome P450; Human CYP2E1 **105**, 217

**Biological-derived medicines**; Safety evaluation; Biotechnology-derived medicines **105**, 59

**Biotechnology-derived medicines**; Safety evaluation; Biological-derived medicines **105**, 59

**Biotechnology-derived products**; Immunotoxicity assessment; Safety evaluation **105**, 1

**Biotechnology**; rDNA-derived products; The new biologies; Toxicologic evaluation **105**, 7

**Biphasic response**; Synergists; Cytochrome P450; Inhibition; Induction; Methylenedioxyphenyl compounds; Benzodioxoles **105**, 211

**Blood plasma, GSH content in**; Antioxidants; Peroxides, detoxication of; Detoxication, role of glutathione in; Apoptosis, redox regulation of; Glutathione; Demographic factors affecting GSH; Diet, GSH content in **105**, 267

**Bootstrap**; Additivity; Conservatism; Likelihood ratio; Monte Carlo; Multistage model **105**, 199

**Carbon tetrachloride**; Chlordecone; Tissue repair; Dose-response for tissue repair; Thioacetamide; Maximum tolerated doses; Risk assessment **105**, 251

0020-7101/95/$09.50 © 1995 Elsevier Science Ireland Ltd. All rights reserved

**Carcinogen**; Additivity; Antagonism; Synergism; Promotion; Interaction **105**, 121

**Chemical exposure**; Chemical mixtures; Risk assesment **105**, 109

**Chemical exposure**; Chemical mixtures; Toxicokinetics; Mathematical models **105**, 209

**Chemical interactions**; Risk assessment; Chemical mixtures **105**, 111

**Chemical interactions**; Risk assessment; Chemical mixtures; Isobolographic analysis **105**, 161

**Chemical mixtures**; Chemical exposure; Toxicokinetics; Mathematical models **105**, 209

**Chemical mixtures**; Chemical interactions; Risk assessment; Isobolographic analysis **105**, 161

**Chemical mixtures**; Departure from additivity; Drug/chemical interaction **105**, 189

**Chemical mixtures**; Epidemiology; Air pollution **105**, 307

**Chemical mixtures**; PB-PK/PD modeling; Risk assessment **105**, 275

**Chemical mixtures**; Respiratory system; Environmental epidemidologist **105**, 305

**Chemical mixtures**; Risk assesment; Chemical exposure **105**, 109

**Chemical mixtures**; Risk åssessment; Air pollution **105**, 315

**Chemical mixtures**; Risk assessment; Chemical interactions **105**, 111

**Chemical mixtures**; Risk assessment; Hazard index; Dose addition; Response addition; Interactions data **105**, 137

**Chemical mixtures**; Risk assessment; Human CYP2E1; Cytochrome P450; Bioactivation **105**, 217

**Chemical mixtures**; Risk assessment; Mathematical modelling **105**, 157

**Chemical mixtures**; Risk assessment; Toxicity **105**, 387

**Chemical mixtures**; Risk assessment; Toxicodynamics; Interactive mechanisms **105**, 235

**Chemical mixtures**; Target organ interactions; PB-PK modeling; Chemical toxicity **105**, 343

**Chemical toxicity**; Target organ interactions; PB-PK modeling; Chemical mixtures **105**, 343

**Chlordecone**; Tissue repair; Carbon tetrachloride; Dose-response for tissue repair; Thioacetamide; Maximum tolerated doses; Risk assessment **105**, 251

**Chlorobenzene**; Hearing loss; Trichloroethylene; Toluene; Xylene; Mixtures **105**, 345

**Competitive inhibition**; Phenol; Hydroquinone; Benzene **105**, 225

**Conservatism**; Bootstrap; Additivity; Likelihood ratio; Monte Carlo; Multistage model **105**, 199

**Contour of constant response**; Interaction index; Isobologram; Response surface; Departures from additivity; Synergism; Antagonism **105**, 181

**Cytochrome P450**; Risk assessment; Chemical mixtures; Human CYP2E1; Bioactivation **105**, 217

**Cytochrome P450**; Synergists; Biphasic response; Inhibition; Induction; Methylenedioxyphenyl compounds; Benzodioxoles **105**, 211

**Cytokine**; Knockout mice; Tumor necrosis factor; Interferon **105**, 69

**Cytokines**; Interferons; Interleukin-2; G-CSF; GM-CSF; Side-effects; Autoimmunity; Immune disorders **105**, 31

**Cytokines**; Lymphocyte subsets; Monkey; Immunotoxicity **105**, 81

**Demographic factors affecting GSH**; Antioxidants; Peroxides, detoxication of; Detoxication, role of glutathione in; Apoptosis, redox regulation of; Blood plasma, GSH content in; Glutathione; Diet, GSH content in **105**, 267

**Defined/complex mixtures**; Study designs; Standard setting **105**, 415

**Departure from additivity**; Drug/chemical interaction; Chemical mixtures **105**, 189

**Departures from additivity**; Interaction index; Contour of constant response; Response surface; Isobologram; Synergism; Antagonism **105**, 181

**Detoxication, role of glutathione in**; Antioxidants; Peroxides, detoxication of; Glutathione; Apoptosis, redox regulation of; Blood plasma, GSH content in; Demographic factors affecting GSH; Diet, GSH content in **105**, 267

**Diet, GSH content in**; Antioxidants; Peroxides, detoxication of; Detoxication, role of glutathione in; Apoptosis, redox regulation of; Blood plasma, GSH content in; Demographic factors affecting GSH; Glutathione **105**, 267

**Dioxin**; TCDD; Glucocorticoid; Ah receptor; Palate **105**, 365
**Dose addition**; Risk assessment; Hazard index; Chemical mixtures; Response addition; Interactions data **105**, 137

**Dose-response for tissue repair**; Chlordecone; Carbon tetrachloride; Tissue repair; Thioacetamide; Maximum tolerated doses; Risk assessment **105**, 251

**Dosimetry**; Particle deposition; Particles; Ozone **105**, 327

**Drug/chemical interaction**; Departure from additivity; Chemical mixtures **105**, 189

**Environmental epidemidologist**; Respiratory system; Chemical mixtures **105**, 305

**Epidemiology**; Chemical mixtures; Air pollution **105**, 307

**G-CSF**; Cytokines; Interferons; Interleukin-2; GM-CSF; Side-effects; Autoimmunity; Immune disorders **105**, 31

**Glucocorticoid**; TCDD; Dioxin; Ah receptor; Palate **105**, 365

**Glutathione**; Antioxidants; Peroxides, detoxication of; Detoxication, role of glutathione in; Apoptosis, redox regulation of; Blood plasma, GSH content in; Demographic factors affecting GSH; Diet, GSH content in **105**, 267

**GM-CSF**; Cytokines; Interferons; Interleukin-2; G-CSF; Side-effects; Autoimmunity; Immune disorders **105**, 31

**Hazard index**; Risk assessment; Chemical mixtures; Dose addition; Response addition; Interactions data **105**, 137

**Hearing loss**; Mixtures; Trichloroethylene; Toluene; Xylene; Chlorobenzene **105**, 345

**Hematotoxicants**; Toxic interactions; PBPK/PD modeling; Physiological pharmacokinetics **105**, 355

**Human CYP2E1**; Risk assessment; Chemical mixtures; Cytochrome P450; Bioactivation **105**, 217

**Hydroquinone**; Phenol; Benzene; Competitive inhibition **105**, 225

**Immune disorders**; Cytokines; Interferons; Interleukin-2; G-CSF; GM-CSF; Side-effects; Autoimmunity **105**, 31

**Immune response**; Interleukin-6; Recombinant human interleukin-6; Megakaryopoiesis; Acute phase reaction **105**, 91

**Immunity**; Asthma; Antigen; Air pollutant; Allergy **105**, 335

**Immunosuppressive agents**; Muromonab CD3; Orthoclone OKT3; Monoclonal antibody; Side-effects **105**, 23

**Immunotoxicity assessment**; Biotechnology-derived products; Safety evaluation **105**, 1

**Immunotoxicity**; Lymphocyte subsets; Cytokines; Monkey **105**, 81

**Induction**; Synergists; Cytochrome P450; Inhibition; Biphasic response; Methylenedioxyphenyl compounds; Benzodioxoles **105**, 211

**Inhibition**; Synergists; Cytochrome P450; Biphasic response; Induction; Methylenedioxyphenyl compounds; Benzodioxoles **105**, 211

**Insecticide**; Organophosphate; Acetylcholinesterase; Acute toxicity; Species differences **105**, 291

**Interaction**; Additivity; Antagonism; Carcinogen; Promotion; Synergism **105**, 121

**Interaction index**; Isobologram; Contour of constant response; Response surface; Departures from additivity; Synergism; Antagonism **105**, 181

**Interactions data**; Risk assessment; Hazard index; Dose addition; Response addition; Chemical mixtures **105**, 137

**Interactions**; Tissue slices; Mixtures; Interspecies **105**, 285

**Interactive mechanisms**; Risk assessment; Toxicodynamics; Chemical mixtures **105**, 235

**Interferon**; Knockout mice; Cytokine; Tumor necrosis factor **105**, 69

**Interferons**; Cytokines; Interleukin-2; G-CSF; GM-CSF; Side-effects; Autoimmunity; Immune disorders **105**, 31

**Interleukin-2**; Cytokines; Interferons; G-CSF; GM-CSF; Side-effects; Autoimmunity; Immune disorders **105**, 31

**Interleukin-6**; Recombinant human interleukin-6; Megakaryopoiesis; Immune response; Acute phase reaction **105**, 91

**Interspecies extrapolation**; Tissue slices; Pesticides **105**, 283

**Interspecies**; Interactions; Mixtures; Tissue slices **105**, 285

**Isobologram**; Interaction index; Contour of constant response; Response surface; Departures from additivity; Synergism; Antagonism **105**, 181

**Isobolographic analysis**; Chemical interactions; Chemical mixtures; Risk assessment **105**, 161

**Knockout mice**; Cytokine; Tumor necrosis factor; Interferon **105**, 69

**Likelihood ratio**; Bootstrap; Conservatism; Additivity; Monte Carlo; Multistage model **105**, 199

**Liver injury**; 2-Nitronaphthalene; Paraquat; Vitamin A; Lung injury; 1-Nitronaphthalene **105**, 237

**Lung injury**; 2-Nitronaphthalene; Paraquat; Vitamin A; 1-Nitronaphthalene; Liver injury **105**, 237

**Lymphocyte subsets**; Cytokines; Monkey; Immunotoxicity **105**, 81

**Mathematical modelling**; Risk assessment; Chemical mixtures **105**, 157

**Mathematical models**; Chemical mixtures; Toxicokinetics; Chemical exposure **105**, 209

**Maximum tolerated doses**; Chlordecone; Carbon tetrachloride; Dose-response for tissue repair; Thioacetamide; Tissue repair; Risk assessment **105**, 251

**Megakaryopoiesis**; Interleukin-6; Recombinant human interleukin-6; Immune response; Acute phase reaction **105**, 91

**Methylenedioxyphenyl compounds**; Synergists; Cytochrome P450; Inhibition; Induction; Biphasic response; Benzodioxoles **105**, 211

**Mixtures**; Hearing loss; Trichloroethylene; Toluene; Xylene; Chlorobenzene **105**, 345

**Mixtures**; Interactions; Tissue slices; Interspecies **105**, 285

**Mixtures**; Risk assessment; Regulatory decision making; Research needs **105**, 429

**Mixtures**; Waste sites; Risk; Public health **105**, 145

**Monkey**; Lymphocyte subsets; Cytokines; Immunotoxicity **105**, 81

**Monoclonal antibody**; Muromonab CD3; Orthoclone OKT3; Side-effects; Immunosuppressive agents **105**, 23

**Monte Carlo**; Bootstrap; Conservatism; Likelihood ratio; Additivity; Multistage model **105**, 199

**Multistage model**; Bootstrap; Conservatism; Likelihood ratio; Monte Carlo; Additivity **105**, 199

**Muromonab CD3**; Orthoclone OKT3; Monoclonal antibody; Side-effects; Immunosuppressive agents **105**, 29

**2-Nitronaphthalene**; 1-Nitronaphthalene; Paraquat; Vitamin A; Lung injury; Liver injury **105**, 237

**1-Nitronaphthalene**; 2-Nitronaphthalene; Paraquat; Vitamin A; Lung injury; Liver injury **105**, 237

**Organophosphate**; Insecticide; Acetylcholinesterase; Acute toxicity; Species differences **105**, 291

**Orthoclone OKT3**; Muromonab CD3; Monoclonal antibody; Side-effects; Immunosuppressive agents **105**, 23

**Ozone**; Dosimetry; Particles; Particle deposition **105**, 327

**Palate**; TCDD; Glucocorticoid; Ah receptor; Dioxin **105**, 365

**Paraquat**; 2-Nitronaphthalene; 1-Nitronaphthalene; Vitamin A; Lung injury; Liver injury **105**, 237

**Particle deposition**; Dosimetry; Particles; Ozone **105**, 327

**Particles**; Dosimetry; Particle deposition; Ozone **105**, 327

**PB-PK modeling**; Target organ interactions; Chemical mixtures; Chemical toxicity **105**, 343

**PB-PK/PD modeling**; Chemical mixtures; Risk assessment **105**, 275

**PBPK/PD modeling**; Hematotoxicants; Toxic interactions; Physiological pharmacokinetics **105**, 355

**Peroxides, detoxication of**; Antioxidants; Glutathione; Detoxication, role of glutathione in; Apoptosis, redox regulation of; Blood plasma, GSH content in; Demographic factors affecting GSH; Diet, GSH content in **105**, 267

**Pesticides**; Tissue slices; Interspecies extrapolation **105**, 283

**Phenol**; Benzene; Hydroquinone; Competitive inhibition **105**, 225

**Physiological pharmacokinetics**; Hematotoxicants; PBPK/PD modeling; Toxic interactions **105**, 355

**Polychlorinated biphenyls**; Toxic equivalency factors (TEFs); 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD); Polychlorinated dibenzofurans; Risk assessment; Polyhalogenated aromatic hydrocarbons **105**, 391

**Polychlorinated dibenzofurans**; Toxic equivalency factors (TEFs); 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD); Risk assessment; Polychlorinated biphenyls; Polyhalogenated aromatic hydrocarbons **105**, 391

**Polyhalogenated aromatic hydrocarbons**; Toxic equivalency factors (TEFs); 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD); Polychlorinated dibenzofurans; Polychlorinated biphenyls; Risk assessment **105**, 391

**Promotion**; Additivity; Antagonism; Carcinogen; Synergism; Interaction **105**, 121

**Public health**; Waste sites; Risk; Mixtures **105**, 145

**rDNA-derived products**; Biotechnology; The new biologies; Toxicologic evaluation **105**, 7

**Recombinant human interleukin-6**; Interleukin-6; Megakaryopoiesis; Immune response; Acute phase reaction **105**, 91

**Regulatory decision making**; Risk assessment; Mixtures; Research needs **105**, 429

**Research needs**; Risk assessment; Regulatory decision making; Mixtures **105**, 429

**Respiratory system**; Chemical mixtures; Environmental epidemidologist **105**, 305

**Response addition**; Risk assessment; Hazard index; Dose addition; Chemical mixtures; Interactions data **105**, 137

**Response surface**; Interaction index; Contour of constant response; Isobologram; Departures from additivity; Synergism; Antagonism **105**, 181

**Risk assesment**; Chemical mixtures; Chemical exposure **105**, 109

**Risk assessment**; Air pollution; Chemical mixtures **105**, 315

**Risk assessment**; Chemical interactions; Chemical mixtures; Isobolographic analysis **105**, 161

**Risk assessment**; Chemical mixtures; Chemical interactions **105**, 111

**Risk assessment**; Chemical mixtures; Hazard index; Dose addition; Response addition; Interactions data **105**, 137

**Risk assessment**; Chemical mixtures; Mathematical modelling **105**, 157

**Risk assessment**; Chemical mixtures; Toxicity **105**, 387

**Risk assessment**; Chemical mixtures; Toxicodynamics; Interactive mechanisms **105**, 235

**Risk assessment**; Chlordecone; Carbon tetrachloride; Dose-response for tissue repair; Thioacetamide; Maximum tolerated doses; Tissue repair **105**, 251

**Risk assessment**; Human CYP2E1; Chemical mixtures; Cytochrome P450; Bioactivation **105**, 217

**Risk assessment**; Mixtures; Regulatory decision making; Research needs **105**, 429

**Risk assessment**; PB-PK/PD modeling; Chemical mixtures **105**, 275

**Risk assessment**; Toxic equivalency factors (TEFs); 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD); Polychlorinated dibenzofurans; Polychlorinated biphenyls; Polyhalogenated aromatic hydrocarbons **105**, 391

**Risk**; Waste sites; Mixtures; Public health **105**, 145

**Safety evaluation**; Biological-derived medicines; Biotechnology-derived medicines **105**, 59

**Safety evaluation**; Immunotoxicity assessment; Biotechnology-derived products **105**, 1

**Side-effects**; Cytokines; Interferons; Interleukin-2; G-CSF; GM-CSF; Autoimmunity; Immune disorders **105**, 31

**Side-effects**; Muromonab CD3; Orthoclone OKT3; Monoclonal antibody; Immunosuppressive agents **105**, 23

**Species differences**; Organophosphate; Acetylcholinesterase; Acute toxicity; Insecticide **105**, 291

**Standard setting**; Study designs; Defined/complex mixtures **105**, 415

**Study designs**; Defined/complex mixtures; Standard setting **105**, 415

**Synergism**; Additivity; Antagonism; Carcinogen; Promotion; Interaction **105**, 121

**Synergism**; Interaction index; Contour of constant response; Response surface; Departures from additivity; Isobologram; Antagonism **105**, 181

**Synergists**; Biphasic response; Cytochrome P450; Inhibition; Induction; Methylenedioxyphenyl compounds; Benzodioxoles **105**, 211

**Target organ interactions**; Chemical mixtures; PB-PK modeling; Chemical toxicity **105**, 343

**TCDD**; Dioxin; Glucocorticoid; Ah receptor; Palate **105**, 365

**2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD)**; Toxic equivalency factors (TEFs); Risk assessment; Polychlorinated dibenzofurans; Polychlorinated biphenyls; Polyhalogenated aromatic hydrocarbons **105**, 391

**The new biologies**; Biotechnology; rDNA-derived products; Toxicologic evaluation **105**, 7

**Thioacetamide**; Chlordecone; Carbon tetrachloride; Dose-response for tissue repair; Tissue repair; Maximum tolerated doses; Risk assessment **105**, 251

**Tissue repair**; Chlordecone; Carbon tetrachloride; Dose-response for tissue repair; Thioacetamide; Maximum tolerated doses; Risk assessment **105**, 251

**Tissue slices**; Interactions; Mixtures; Interspecies **105**, 285

**Tissue slices**; Interspecies extrapolation; Pesticides **105**, 283

**Toluene**; Hearing loss; Trichloroethylene; Mixtures; Xylene; Chlorobenzene **105**, 345

**Toxic equivalency factors (TEFs)**; Risk assessment; 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD); Polychlorinated dibenzofurans; Polychlorinated biphenyls; Polyhalogenated aromatic hydrocarbons **105**, 391

**Toxic interactions**; Hematotoxicants; PBPK/PD modeling; Physiological pharmacokinetics **105**, 355

**Toxicity**; Risk assessment; Chemical mixtures **105**, 387

**Toxicodynamics**; Risk assessment; Chemical mixtures; Interactive mechanisms **105**, 235

**Toxicokinetics**; Chemical mixtures; Chemical exposure; Mathematical models **105**, 209

**Toxicologic evaluation**; Biotechnology; rDNA-derived products; The new biologies **105**, 7

**Trichloroethylene**; Hearing loss; Mixtures; Toluene; Xylene; Chlorobenzene **105**, 345

**Tumor necrosis factor**; Knockout mice; Cytokine; Interferon **105**, 69

**Vitamin A**; 2-Nitronaphthalene; Paraquat; 1-Nitronaphthalene; Lung injury; Liver injury **105**, 237

**Waste sites**; Mixtures; Risk; Public health **105**, 145

**Xylene**; Hearing loss; Trichloroethylene; Toluene; Mixtures; Chlorobenzene **105**, 345